[SCHEDULE 13G/A] Protagenic Therapeutics, Inc. Warrant SEC Filing

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. (PTIXW) received a Schedule 13G/A filed by Bigger Capital Fund, LP; Bigger Capital Fund GP, LLC; and Michael Bigger reporting their relationship to the issuer's Common Stock (CUSIP 74365N202). The filing states that as of August 22, 2025, each Reporting Person owned no shares of the issuer and reported 0% ownership. The filing includes addresses and citizenship information for each Reporting Person and certifications that the securities were not acquired to influence control of the issuer. Signatures executed by Michael Bigger certify the accuracy of the statement.

Insights

Financial Analyst

TL;DR: Schedule 13G/A shows no beneficial ownership by the listed reporting persons, producing no direct market impact.

The filing discloses that Bigger Capital Fund, LP, Bigger Capital Fund GP, LLC, and Michael Bigger report zero shares beneficially owned of Protagenic Therapeutics common stock as of August 22, 2025. From an investor-impact perspective, this is a neutral disclosure: it confirms an absence of stake rather than a material acquisition or disposition. The document supplies contact and organizational details and includes the required certification language attesting that ownership is not intended to influence control.

Corporate Governance Expert

TL;DR: Filing appears compliant and clear; lack of ownership means no change to governance influence by the reporting group.

For governance considerations, the Schedule 13G/A provides the formal identification of the Reporting Persons and affirms 0% ownership, indicating they hold no voting or dispositive power over Protagenic Therapeutics' common stock. The signatures and certification statements are present, fulfilling procedural requirements. Because no securities are held, there is no shift in control rights or group-based coordination to scrutinize.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Protagenic Therapeutics, Inc.\new

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

74365N202

(CUSIP Number)

08/22/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74365N202

1

Names of Reporting Persons

BIGGER CAPITAL FUND L P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 74365N202

1

Names of Reporting Persons

Bigger Capital Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 74365N202

1

Names of Reporting Persons

Bigger Michael

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Protagenic Therapeutics, Inc.\new
(b)	Address of issuer's principal executive offices: 149 Fifth Avenue, Suite 500, New York, NY 10010
Item 2.
(a)	Name of person filing: Bigger Capital Fund, LP ("Bigger Capital") Bigger Capital Fund GP, LLC ("Bigger GP") Michael Bigger Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: Bigger Capital Fund, LP 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135 Bigger Capital Fund GP, LLC 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135 Michael Bigger 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135
(c)	Citizenship: Bigger Capital Fund, LP Delaware Bigger Capital Fund GP, LLC Delaware Michael Bigger USA
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 74365N202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of August 22, 2025, each of the Reporting Persons owned no securities of the Issuer.
(b)	Percent of class: Not Applicable.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1. Previously Filed
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIGGER CAPITAL FUND L P

Signature:	/s/ Michael Bigger
Name/Title:	Michael Bigger, Managing Member of Bigger Capital Fund GP, LLC, its general partner
Date:	08/25/2025

Bigger Capital Fund GP, LLC

Signature:	/s/ Michael Bigger
Name/Title:	Michael Bigger, Managing Member
Date:	08/25/2025

Bigger Michael

Signature:	/s/ Michael Bigger
Name/Title:	Michael Bigger
Date:	08/25/2025

FAQ

What does the Schedule 13G/A filed for PTIXW state about ownership?

The filing states that Bigger Capital Fund, LP; Bigger Capital Fund GP, LLC; and Michael Bigger each beneficially own 0 shares of Protagenic Therapeutics common stock as of August 22, 2025.

Who signed the Schedule 13G/A for Protagenic Therapeutics (PTIXW)?

The Schedule 13G/A is signed by Michael Bigger in his capacities as Managing Member of Bigger Capital Fund GP, LLC and as an individual, dated August 25, 2025.

Does the filing indicate any intention to influence control of Protagenic Therapeutics (PTIXW)?

The certification in the filing states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What class of securities is covered by the Schedule 13G/A for PTIXW?

The filing covers the issuer's Common Stock, par value $0.0001 per share, CUSIP 74365N202.

As of what date does the Schedule 13G/A report ownership for PTIXW?

Ownership is reported as of August 22, 2025.